Title : A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD.

Pub. Date : 2003 Dec 9

PMID : 14663007






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Importantly, the selective A2A antagonist KW6002 reverses motor disability and increases locomotor activity in MPTP-treated primates without provoking dyskinesia established by previous exposure to L-dopa. istradefylline spectrin, alpha, non-erythrocytic 1 Rattus norvegicus
2 The data available suggest that A2A antagonists, such as KW6002, may be effective as monotherapy for the management of PD and that they will also produce additional benefit when administered in combination with L-dopa or dopamine agonist therapy. istradefylline spectrin, alpha, non-erythrocytic 1 Rattus norvegicus